A systemic analysis of the technological trajectory at company level based on patent data: The case of Sanofi's vaccine technology

Sophie Boutillier (), Blandine Laperche (), Didier Lebert and Sana Elouaer-Mrizak ()
Additional contact information
Sophie Boutillier: ISI - Centre de recherche sur l’Innovation et les Stratégies Industrielles - ULCO - Université du Littoral Côte d'Opale
Blandine Laperche: ISI - Centre de recherche sur l’Innovation et les Stratégies Industrielles - ULCO - Université du Littoral Côte d'Opale
Didier Lebert: UEA - Unité d'Économie Appliquée - ENSTA Paris - École Nationale Supérieure de Techniques Avancées - IP Paris - Institut Polytechnique de Paris, CRG I3 - Centre de recherche en gestion I3 - X - École polytechnique - IP Paris - Institut Polytechnique de Paris - I3 - Institut interdisciplinaire de l’innovation - CNRS - Centre National de la Recherche Scientifique
Sana Elouaer-Mrizak: ISI - Centre de recherche sur l’Innovation et les Stratégies Industrielles - ULCO - Université du Littoral Côte d'Opale

Post-Print from HAL

Abstract: Whereas most of technological trajectory research in evolutionary economics focuses on the sectoral level, our objective is to propose an analysis at the scale of the company. We are studying the leading pharmaceutical company Sanofi and focusing on the development of its vaccine technologies, a very topical issue in the Covid-19 context. What are the characteristics of Sanofi's vaccine technology trajectory and how can they explain the company's position in the Covid-19 crisis, i.e. its ability (or not) to innovate and respond to social demand for a vaccine? We contribute to technological trajectory literature by integrating a systemic dimension of the links between source and destination technology. Our ‘Knowledge Capital Approach' is based on patent citation data and network analysis. It has allowed us to identify the trajectory of Sanofi's vaccine technical system and to show its central position in its knowledge capital, where the technologies mastered by the company converge. These results can be viewed as paradoxical when considering Sanofi's lag in the Covid-19 race for a new vaccine. Our historical and qualitative approach adds to these findings by showing the role of strategic and institutional factors in explaining this situation.

Keywords: Technological trajectory; Knowledge capital; Sanofi; Vaccine technical system; Network analysis (search for similar items in EconPapers)
Date: 2023-06
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Published in Technovation, 2023, 124, pp.102746. ⟨10.1016/j.technovation.2023.102746⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:halshs-04028255

DOI: 10.1016/j.technovation.2023.102746

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().